{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T04:59:19Z","timestamp":1764997159336},"reference-count":21,"publisher":"Wiley","issue":"S1","license":[{"start":{"date-parts":[[2018,2,28]],"date-time":"2018-02-28T00:00:00Z","timestamp":1519776000000},"content-version":"vor","delay-in-days":27,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2018,2]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>People who inject drugs (PWID) represent the main risk group for hepatitis C virus (HCV) infection in most middle and high\u2010income countries. Testing PWID is considered as an important prevention measure. Identification of PWID characteristics associated with HCV testing may contribute to strategies targeting the containment of the HCV and HIV epidemics in Greece.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Anonymous behavioural data from 2747 heroin users were collected upon entry in 38 opioid substitution treatment (OST) clinics in Greece during the period 2013\u20132015. HCV test uptake was the dependent variable while covariates included sociodemographic and addiction\u2010related variables, mostly derived from the EMCDDA treatment demand indicator protocol.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 2299 cases with complete data on HCV testing, 83.5% reported any HCV testing uptake, with 61.2% reporting a recent test (&lt;\u00a012\u00a0months). In the multivariate analyses, any previous HCV testing uptake was associated with age \u2265\u00a025\u00a0years, past drug treatment attempt, injecting or sniffing the primary substance, injection history \u2265\u00a05\u00a0years, and syringe sharing earlier than the past 12\u00a0months. <jats:italic>Past<\/jats:italic> HCV test uptake was higher among those reporting full\u2010time employment and 2\u20134\u00a0years injecting histories, and lower among residents of Athens. <jats:italic>Recent<\/jats:italic> testing was positively associated with female gender and polysubstance use.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Any previous HCV testing uptake is high among PWID entering OST in Greece and is associated with older age, longer injecting histories and past drug\u2010related treatment attempts. Efforts to prevent and mitigate the ongoing HCV test epidemic among PWID in Greece should combine treatment with scaling up of screening, targeting especially those younger than 25\u00a0years and at the beginning of their hazardous use.<\/jats:p><\/jats:sec>","DOI":"10.1111\/hiv.12589","type":"journal-article","created":{"date-parts":[[2018,2,28]],"date-time":"2018-02-28T05:45:28Z","timestamp":1519796728000},"page":"34-39","source":"Crossref","is-referenced-by-count":5,"title":["Factors associated with HCV test uptake in heroin users entering substitution treatment in Greece"],"prefix":"10.1111","volume":"19","author":[{"given":"O","family":"Anagnostou","sequence":"first","affiliation":[{"name":"Greek Organisation Against Drugs (OKANA) Athens Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Fotiou","sequence":"additional","affiliation":[{"name":"Greek Reitox Focal Point of the EMCDDA Athens University Mental Health Research Institute (UMHRI) Athens Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Kanavou","sequence":"additional","affiliation":[{"name":"Greek Reitox Focal Point of the EMCDDA Athens University Mental Health Research Institute (UMHRI) Athens Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Antaraki","sequence":"additional","affiliation":[{"name":"Greek Reitox Focal Point of the EMCDDA Athens University Mental Health Research Institute (UMHRI) Athens Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Terzidou","sequence":"additional","affiliation":[{"name":"Greek Reitox Focal Point of the EMCDDA Athens University Mental Health Research Institute (UMHRI) Athens Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Richardson","sequence":"additional","affiliation":[{"name":"Panteion University of Social and Political Sciences Athens Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Kafetzopoulos","sequence":"additional","affiliation":[{"name":"Greek Organisation Against Drugs (OKANA) Athens Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"The Drug Related Infectious Diseases (DRID) Medical Doctors Group of OKANA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,2,28]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.03.015"},{"volume-title":"Prevention and Control of Infectious Diseases Among People Who Inject Drugs","year":"2011","author":"European Centre for Disease Control and Prevention [ECDC] & European Monitoring Centre for Drugs and Drug Addiction [EMCDDA]","key":"e_1_2_6_3_1"},{"key":"e_1_2_6_4_1","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/cid\/cit938","article-title":"Sustained drug use changes after hepatitis C screening and counseling among recently infected persons who inject drugs: a longitudinal study","volume":"58","author":"Bruneau J","year":"2013","journal-title":"Clin Infect Dis"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.08.029"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit377"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2010.03.006"},{"volume-title":"WHO guidelines on hepatitis B and C testing","year":"2017","author":"WHO","key":"e_1_2_6_8_1"},{"issue":"5","key":"e_1_2_6_9_1","doi-asserted-by":"crossref","first-page":"S276","DOI":"10.1086\/427441","article-title":"Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users","volume":"40","author":"Edlin BR","year":"2005","journal-title":"Clin Infect Dis"},{"volume-title":"Greece, Country Drug Report 2017","year":"2017","author":"European Monitoring Centre for Drugs and Drug Addiction","key":"e_1_2_6_10_1"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.2807\/ese.16.36.19962-en"},{"key":"e_1_2_6_12_1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s41124-016-0017-5","article-title":"HCV\/HIV coinfection among people who inject drugs and enter opioid substitution treatment in Greece: prevalence and correlates","volume":"1","author":"Fotiou A","year":"2016","journal-title":"Hepatol Med Policy"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S49113"},{"key":"e_1_2_6_14_1","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1186\/1471-2458-13-899","article-title":"HIV and hepatitis C virus test uptake at methadone clinics in Southern China: opportunities for expanding detection of bloodborne infections","volume":"13","author":"Xia Y\u2010H","year":"2013","journal-title":"BMC Public Health"},{"key":"e_1_2_6_15_1","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/pubmed\/fds105","article-title":"Low rates of hepatitis C testing among people who inject drugs in Thailand: implications for peer\u2010based interventions","volume":"35","author":"Ti L","year":"2013","journal-title":"J Public Health"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jadohealth.2005.02.015"},{"key":"e_1_2_6_17_1","doi-asserted-by":"crossref","first-page":"38","DOI":"10.4038\/ijptsud.v1i3-4.7837","article-title":"Uptake of HIV, Hepatitis B and Hepatitis C testing among injection drug users in Thailand","volume":"1","author":"Khampang R","year":"2015","journal-title":"Int J Prev Treat Subst Use Disorders"},{"volume-title":"Treatment demand indicator (TDI), Standard protocol 3.0: Guidelines for reporting data on people entering drug treatment in European countries","year":"2012","author":"European Monitoring Centre for Drugs and Drug Addiction","key":"e_1_2_6_18_1"},{"key":"e_1_2_6_19_1","unstructured":"TouloumiP.National epidemiological study of infectious diseases \u201cHprolipsis\u201d: Final results. 24th International Hepatitis \u0392 & C Meeting of Athens \u201cHadziyannis\u201d; 28 & 29 January 2017; Athens 2017."},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.86.5.655"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000157006.28535.mL"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/s41124-016-0016-6"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fhiv.12589","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.12589","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T11:25:58Z","timestamp":1694431558000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hiv.12589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":21,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["10.1111\/hiv.12589"],"URL":"https:\/\/doi.org\/10.1111\/hiv.12589","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"type":"print","value":"1464-2662"},{"type":"electronic","value":"1468-1293"}],"subject":[],"published":{"date-parts":[[2018,2]]}}}